

BIOCON GROUP

FACT SHEET

September - 2020

BIOCON LIMITED (CONSOLIDATED)
BALANCE SHEET

(Rs Crores)

Particulars	September 30, 2020	March 31, 2020
ASSETS		
Non-current assets		
(a) Property, plant and equipment	5,305	5,393
(b) Capital work-in-progress	1,914	1,577
(c) Goodwill	26	26
(d) Other intangible assets	568	423
(e) Intangible assets under development	516	620
(f) Right-of-use assets	157	128
(g) Investment in associates and a joint venture	-	14
(h) Financial assets		
Investments	112	94
Derivative assets	42	26
Other financial assets	60	56
(i) Income tax asset, net	274	242
(j) Deferred tax asset, net	368	368
(k) Other non-current assets	137	151
Non-current assets	9,480	9,119
Current assets		
(a) Inventories	1,642	1,436
(b) Financial assets		
Investments	838	858
Trade receivables	1,228	1,224
Cash and cash equivalents	1,063	910
Other bank balances	355	89
Derivative assets	48	19
Other financial assets	733	450
(c) Other current assets	404	340
(c) Assets held for sale	70	-
Current assets	6,380	5,325
TOTAL - ASSETS	15,860	14,444
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	600	600
(b) Other equity	6,455	6,106
Equity attributable to owners of the Company	7,055	6,706
Non-controlling interests	769	677
Total Equity	7,824	7,383
Non-current liabilities		
(a) Financial liabilities		
Borrowings	1,952	1,222
Lease liabilities	114	83
Derivative liabilities	120	146
Other financial liabilities	865	536
(b) Provisions	97	86
(c) Deferred tax liability, net	35	30
(d) Other non-current liabilities	943	949
Non-current liabilities	4,126	3,053
Current liabilities		
(a) Financial liabilities		
Borrowings	611	668
Lease liabilities	10	7
Trade payables	1,441	1,325
Derivative liabilities	41	72
Other financial liabilities	1,094	1,208
(b) Provisions	114	103
(c) Income tax liability, net	179	128
(d) Other current liabilities	362	498
(e) Liabilities classified as held for sale	59	-
Current liabilities	3,910	4,008
TOTAL - EQUITY AND LIABILITIES	15,860	14,444

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	Q2' FY 21	Q2' FY 20	Variance %
INCOME			
Generics	599	553	8%
Biosimilars	676	607	11%
Novel Biologics	-	-	-
Research services	520	465	12%
Inter-segment	(50)	(57)	-13%
Revenue from operations #	1,745	1,567	11%
Other income	16	38	-60%
TOTAL REVENUE	1,760	1,606	10%
EXPENDITURE			
Material & Power costs	601	545	10%
Staff costs	383	322	19%
Research & Development expenses*	148	104	42%
Other expenses	222	193	15%
Manufacturing, staff & other expenses	1,353	1,165	16%
EBITDA	407	441	-8%
Interest & Finance charges	7	14	-53%
Depreciation & Amortisation	178	132	35%
PBT BEFORE EXCEPTIONAL ITEM	223	296	-25%
Exceptional item, Net	-	68	-
PBT FROM CONTINUING OPERATIONS	223	363	-39%
Taxes	22	73	-70%
Taxes on exceptional item	-	27	-100%
NET PROFIT BEFORE MINORITY INTEREST	200	263	-24%
Minority interest	26	24	7%
Minority interest on exceptional item	-	14	-
NET PROFIT FOR THE PERIOD FROM CONTINUING OPERATIONS	174	225	-23%
LOSS FROM DISCONTINUING OPERATION	5	9	-47%
NET PROFIT FOR THE PERIOD	169	216	-22%
EPS Rs.	1.4	1.8	
NET PROFIT BEFORE EXCEPTIONAL ITEM AND DISCONTINUING OPERATION	174	198	-12%
Loss from discontinuing operation	5	9	-47%
Exceptional item, net of taxes	-	27	-100%
NET PROFIT FOR THE PERIOD	169	216	-22%
# Licensing Income	11	7	
* Gross Research & Development expenses	165	123	

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT

(Rs. Crores)

Particulars	Q2' FY 21	Q1' FY 21	Variance %
INCOME			
Generics	599	599	0%
Biosimilars	676	692	-2%
Novel Biologics	-	-	-
Research services	520	422	23%
Inter-segment	(50)	(41)	22%
Revenue from operations #	1,745	1,671	4%
Other income	16	18	-15%
TOTAL REVENUE	1,760	1,690	4%
EXPENDITURE			
Material & Power costs	601	603	0%
Staff costs	383	359	7%
Research & Development expenses*	148	107	39%
Other expenses	222	190	17%
Manufacturing, staff & other expenses	1,353	1,258	8%
EBITDA	407	432	-6%
Interest & Finance charges	7	13	-48%
Depreciation & Amortisation	178	167	7%
PBT BEFORE EXCEPTIONAL ITEM	223	252	-12%
Exceptional item, Net	-	-	-
PBT FROM CONTINUING OPERATIONS	223	252	-12%
Taxes	22	81	-72%
Taxes on exceptional item	-	-	0%
NET PROFIT BEFORE MINORITY INTEREST	200	171	17%
Minority interest	26	18	42%
Minority interest on exceptional item	-	-	-
NET PROFIT FOR THE PERIOD FROM CONTINUING OPERATIONS	174	153	14%
LOSS FROM DISCONTINUING OPERATION	5	4	39%
NET PROFIT FOR THE PERIOD	169	149	13%
EPS Rs.	1.4	1.2	
NET PROFIT BEFORE DISCONTINUING OPERATION	174	153	14%
Loss from discontinuing operation	5	4	39%
Exceptional item, net of taxes	-	-	-
NET PROFIT FOR THE PERIOD	169	149	13%
# Licensing Income	11	10	
* Gross Research & Development expenses	165	142	

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT

(Rs. Crores)

Particulars	H1' FY 21	H1' FY 20	Variance %
INCOME			
Generics	1,198	1,069	12%
Biosimilars	1,368	1,189	15%
Novel Biologics	-	-	-
Research services	941	886	6%
Inter-segment	(91)	(117)	-23%
Revenue from operations #	3,416	3,026	13%
Other income	34	63	-46%
TOTAL REVENUE	3,450	3,089	12%
EXPENDITURE			
Material & Power costs	1,203	1,029	17%
Staff costs	742	631	17%
Research & Development expenses*	255	183	39%
Other expenses	412	342	20%
Manufacturing, staff & other expenses	2,611	2,186	19%
EBITDA	839	903	-7%
Interest & Finance charges	19	30	-38%
Depreciation & Amortisation	345	256	35%
PBT BEFORE EXCEPTIONAL ITEM	475	617	-23%
Exceptional item, Net	-	68	-
PBT FROM CONTINUING OPERATIONS	475	684	-31%
Taxes	103	142	-27%
Taxes on exceptional item	-	44	-100%
NET PROFIT BEFORE MINORITY INTEREST	372	499	-25%
Minority interest	45	46	-3%
Minority interest on exceptional item	-	14	-
NET PROFIT FOR THE PERIOD FROM CONTINUING OPERATIONS	327	439	-25%
LOSS FROM DISCONTINUING OPERATION	9	17	-50%
NET PROFIT FOR THE PERIOD	319	422	-24%
EPS Rs.	2.7	3.5	
NET PROFIT BEFORE DISCONTINUING OPERATION	327	439	-25%
Loss from discontinuing operation	9	17	-50%
Exceptional item, net of taxes	-	10	
NET PROFIT FOR THE PERIOD	319	422	-24%
# Licensing Income	21	14	
* Gross Research & Development expenses	308	233	